LONDON, UK: Open Orphan plc, a rapidly growing contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials, has appointed Yamin ‘Mo’ Khan as Chief Executive Officer with immediate effect. Mo joined the Board as a Non-Executive Director (“NED”) in October 2021 and has worked closely with the…
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care…
LONDON: Open Orphan has received Court approval for the reduction in capital. The reduction of capital will become effective on registration of the Court order at Companies House, which is expected to occur in the next few days. The reduction of capital will give the Company the ability to not only effect the Distribution in…
LONDON: Open Orphan plc (ORPH) announced the signing of a contract by hVIVO, a subsidiary of Open Orphan, with the UK Government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus. The contract starts immediately and could…
LONDON: Open Orphan plc (ORPH), announced a new £4.3 million contract to conduct a human viral challenge study utilising one of its 8 traditional challenge study models for another of the global top 10 vaccine companies. This trial will be conducted in the Company’s dedicated human viral challenge quarantine unit in London with all volunteers…